Viking Therapeutics to release second-quarter 2026 results on July 29
The Nasdaq-listed biotech company said it will report June-quarter financial results after the market close and host a conference call later that day with corporate updates.
Viking Therapeutics, Inc. said it will release second-quarter 2026 financial results after the market close on Wednesday, July 29, 2026, and hold a conference call at 4:30 p.m. Eastern Time to discuss the results and provide general corporate updates. The clinical-stage biopharmaceutical company, which trades on Nasdaq under the ticker VKTX, is focused on therapies for metabolic and endocrine disorders, with a pipeline centered on obesity and related diseases. Its lead candidate, VK2735, is a dual GLP-1 and GIP receptor agonist being developed in subcutaneous and oral formulations for obesity and is being evaluated in Phase 3 studies, alongside a Phase 1 study on maintenance dosing for long-term weight management. Viking's pipeline also includes VK3019, an amylin receptor agonist, VK2809 for metabolic and liver disease, and VK0214 for X-linked adrenoleukodystrophy.
- GLP-1 and GIP receptor agonist: A drug designed to activate the GLP-1 and GIP hormone pathways, which are involved in appetite, blood sugar and weight regulation.
- Phase 3 clinical studies: Late-stage trials that test a treatment in larger patient groups to confirm effectiveness and monitor safety before possible regulatory submission.
- amylin receptor agonist: A therapy intended to mimic amylin, a hormone linked to slowing digestion and increasing feelings of fullness.